Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
Vincent Poher, Chief Executive Officer at BIOCELLIS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Thrombosis Research, adding:
“A little late in sharing this, but perhaps at the right time.
Last May, Thrombosis Research published the first full analytical and clinical validation of the Tsmart FIB Batrox assay on the LabPad Evolution platform.
The study demonstrated strong correlation with the laboratory Clauss method (r = 0.94), excellent diagnostic performance at the clinically critical 1 and 2 g/L thresholds (where it matters most for severe bleeding), and rapid quantitative fibrinogen measurement from citrated whole blood.
Importantly, the assay was also shown to be insensitive to major anticoagulants tested, including heparins and DOACs.
This last point is particularly important for us.
Our chemistry could make rapid fibrinogen measurement especially relevant in highly anticoagulated environments such as cardiac surgery, extracorporeal circulation and critical care, where every minute matters.
Congratulations to the entire team and all our clinical and scientific partners who contributed to this important milestone!
Following the acquisition of the key LabPad assets and technology by Biocellis, we are fully restarting the LabPad program.
This publication is therefore more than the conclusion of years of development.
It is the scientific foundation for a new chapter, with the ambition to bring LabPad back to the market and develop a broader point-of-care haemostasis platform.
And this is only the first of several clinical publications to come.
More to come!”
Title: Analytical and clinical validation of the Tsmart FIB Batrox assay on the LabPad Evolution analyzer for fibrinogen measurement in whole blood
Authors: Nina Breteau, Corinne Frère, Raphaël Marlu, Landry Seyve, Stéphane Blachier, Vincent Poher, Johanna Spiaczka, Benoît Polac

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities
-
Aug 27, 2026, 10:43FDA Expands Hympavzi Approval to Children and Patients With Hemophilia A or B With Inhibitor
-
Aug 27, 2026, 10:28Narat Srivali: Exploring the Link Between Perioperative Corticosteroids and VTE Risk
-
Aug 27, 2026, 07:49Denis Oduor: Bringing Blood Closer – Strengthening Kenya’s Response to PPH
-
Aug 27, 2026, 07:19Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
-
Aug 27, 2026, 06:58Priyam Bordoloi: The Biological Advantage of Two X Chromosomes
-
Aug 27, 2026, 00:14Join EHA ReCon 2027 in Malta – Explore RNA Biology to Therapeutics